P725 A prospective study of planned switch from Infliximab originator remicade to biosimilar inflectra: a multi-centre Irish experience
N. McGettigan*1, C. Mc Shane2, O. Mc Carthy1, A. Keogh1, D. Kevans2, E. Slattery1
1Galway University Hospital, Gastroenterology, Galway, Ireland, 2St James Hospital, Gastroenterology, Dublin, Ireland
Infliximab (IFX) biosimilars were approved in 2013 by the EMA. Since then, studies have shown the efficacy of IFX biosimilars appear similar to Remicade when patients are switched. The main reason for switch to bio-similar is the associated cost reduction with recent reports of cost savings up to 69%. Our aim was to prospectively assess the efficacy, safety and patient satisfaction when patients were switched from Remicade to Inflectra.
This is an open-label, non-inferiority, prospective cohort study from two Tertiary Irish hospitals involving patients with IBD >18 years receiving Remicade who were switched to Inflectra between October 2017 and August 2018. Data were collected at intervals of 3 months. Patient CRP, faecal calprotectin, IFX trough levels and antibodies (Abs) to IFX were collected.
74 patients were included in the study. Sixty-nine per cent (
Mean CRP Pre and Post switch
Our study demonstrates the efficacy of switching to biosimilar without concern regarding safety or immunogenicity. There was no change in clinical remission rates following the switch. The majority of patients remained on Inflectra at 6 months and the switch resulted in a significant cost reduction. We aim to collect further 6 and 12 month data prior to the congress.